Myriad Tells Justices To Reject ACLU Gene Patent Challenge

Law360, New York (November 5, 2012, 5:56 PM EST) -- Myriad Genetics Inc. urged the U.S. Supreme Court on Wednesday not to hear a challenge to its breast cancer gene patents, saying that the Federal Circuit correctly held that isolated DNA molecules are patent-eligible subject matter.

The American Civil Liberties Union asked the high court in September to review the Federal Circuit's finding that isolated DNA can be patented because it is a man-made composition different from naturally occurring DNA. The group said the court failed to correctly apply the Supreme Court's March ruling in Mayo...
To view the full article, register now.